ZA200705083B - Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders - Google Patents
Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disordersInfo
- Publication number
- ZA200705083B ZA200705083B ZA200705083A ZA200705083A ZA200705083B ZA 200705083 B ZA200705083 B ZA 200705083B ZA 200705083 A ZA200705083 A ZA 200705083A ZA 200705083 A ZA200705083 A ZA 200705083A ZA 200705083 B ZA200705083 B ZA 200705083B
- Authority
- ZA
- South Africa
- Prior art keywords
- agonist
- prevention
- treatment
- neurodegenerative disorders
- neurodegenerative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63576604P | 2004-12-14 | 2004-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200705083B true ZA200705083B (en) | 2010-03-31 |
Family
ID=36177731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200705083A ZA200705083B (en) | 2004-12-14 | 2007-06-13 | Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders |
Country Status (15)
Country | Link |
---|---|
US (1) | US20060128744A1 (en) |
EP (1) | EP1824464A1 (en) |
JP (1) | JP2008523146A (en) |
KR (1) | KR20070088770A (en) |
CN (1) | CN101098683A (en) |
AU (1) | AU2005316675A1 (en) |
BR (1) | BRPI0519036A2 (en) |
CA (1) | CA2590841A1 (en) |
CR (1) | CR9200A (en) |
IL (1) | IL183859A0 (en) |
MX (1) | MX2007007206A (en) |
NO (1) | NO20073104L (en) |
RU (1) | RU2007122450A (en) |
WO (1) | WO2006065710A1 (en) |
ZA (1) | ZA200705083B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200301251A (en) * | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
JP2005305107A (en) * | 2004-03-25 | 2005-11-04 | Sei Matsuoka | Apparatus and method for measuring quantitative value of information |
EP2027087A2 (en) | 2006-05-18 | 2009-02-25 | MannKind Corporation | Intracellular kinase inhibitors |
EP1953153A1 (en) * | 2007-01-31 | 2008-08-06 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders |
US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
CN104276993B (en) * | 2013-07-12 | 2019-03-15 | 广东东阳光药业有限公司 | Indole derivatives and its application on drug |
CN104557664B (en) * | 2013-10-19 | 2020-01-21 | 广东东阳光药业有限公司 | Aromatic heterocyclic derivative and application thereof in medicines |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
IL162243A0 (en) * | 2001-12-20 | 2005-11-20 | Wyeth Corp | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
UA78999C2 (en) * | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
-
2005
- 2005-12-12 EP EP05853687A patent/EP1824464A1/en not_active Withdrawn
- 2005-12-12 WO PCT/US2005/044820 patent/WO2006065710A1/en active Application Filing
- 2005-12-12 KR KR1020077015556A patent/KR20070088770A/en not_active Application Discontinuation
- 2005-12-12 RU RU2007122450/14A patent/RU2007122450A/en not_active Application Discontinuation
- 2005-12-12 CA CA002590841A patent/CA2590841A1/en not_active Abandoned
- 2005-12-12 BR BRPI0519036-3A patent/BRPI0519036A2/en not_active IP Right Cessation
- 2005-12-12 AU AU2005316675A patent/AU2005316675A1/en not_active Abandoned
- 2005-12-12 CN CNA2005800464202A patent/CN101098683A/en not_active Withdrawn
- 2005-12-12 JP JP2007546799A patent/JP2008523146A/en not_active Withdrawn
- 2005-12-12 MX MX2007007206A patent/MX2007007206A/en unknown
- 2005-12-13 US US11/301,445 patent/US20060128744A1/en not_active Abandoned
-
2007
- 2007-06-12 IL IL183859A patent/IL183859A0/en unknown
- 2007-06-13 ZA ZA200705083A patent/ZA200705083B/en unknown
- 2007-06-18 NO NO20073104A patent/NO20073104L/en not_active Application Discontinuation
- 2007-06-20 CR CR9200A patent/CR9200A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2008523146A (en) | 2008-07-03 |
RU2007122450A (en) | 2009-01-27 |
MX2007007206A (en) | 2008-03-26 |
CA2590841A1 (en) | 2006-06-22 |
WO2006065710A1 (en) | 2006-06-22 |
CN101098683A (en) | 2008-01-02 |
KR20070088770A (en) | 2007-08-29 |
AU2005316675A1 (en) | 2006-06-22 |
EP1824464A1 (en) | 2007-08-29 |
US20060128744A1 (en) | 2006-06-15 |
CR9200A (en) | 2007-09-07 |
NO20073104L (en) | 2007-07-02 |
BRPI0519036A2 (en) | 2008-12-23 |
IL183859A0 (en) | 2008-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1190084A1 (en) | Crig polypeptide for prevention and treatment of complement-associated disorders crig | |
ZA200607433B (en) | Methods and compositions for the treatment of gastroin-testinal disorders | |
IL175055A0 (en) | Combinations useful for the treatment of neuronal disorders | |
IL230241A (en) | Retinal derivatives and methods for the use thereof for the treatment of visual disorders | |
IL179508A0 (en) | 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders | |
IL180108A0 (en) | Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders | |
ZA200703601B (en) | Medicaments for the treatment or prevention of fibriotic diseases | |
IL181706A0 (en) | The treatment of inflammatory disorders and pain | |
GB0610350D0 (en) | prevention and/or treatment of neuodegenerative disorders | |
IL183656A0 (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders | |
IL182574A0 (en) | Gpr41 and modulators thereof for the treatment of insulin-related disorders | |
IL187248A0 (en) | Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders | |
ZA200705083B (en) | Use of a 5-HT6 agonist for the treatment and prevention of neurodegenerative disorders | |
IL177955A0 (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
PT2054045E (en) | Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain | |
EP2077838A4 (en) | Methods for the treatment of a related disorders and compositions therefor | |
IL193799A0 (en) | New therapeutic combinations for the treatment or prevention of psycotic disorders | |
EP1812009A4 (en) | Gaba-steroid antagonists and their use for the treatment of cns disorders | |
IL193943A0 (en) | The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain | |
PL1727545T3 (en) | Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies | |
EP1776956A4 (en) | Preventive and/or therapeutic agent for calcipenia | |
IL193944A0 (en) | The use beta-aminoalcohols for the treatment of inflammatory disorders and pain | |
EP1928473A4 (en) | Combination of polychitosamine and fibrate for the prevention and treatment of hyperlipidemia | |
GB0419828D0 (en) | The treatment of inflammatroy disorders and pain | |
GB0513413D0 (en) | The treatment of inflammatory disorders and pain |